The early diagnostic value of DNA methylation analysis in circulating cell-free DNA of pancreaitc cancer patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061577

Enrollment

Unknown

Registered

2022-06-29

Start date

2022-06-15

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Gold Standard:Pathologically confirmed as pancreatic cancer

in&#32

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Imaging diagnosis of resectable pancreatic cancer without neoadjuvant therapy, and pathologically confirmed; 2. Imaging diagnosis of borderline resectable or unresectable pancreatic cancer, and pathologically confirmed; 3. Imaging findings suggested suspected lesions of pancreatic cancer; 4. Patients carrying risk factors of pancreatic cancer;

Exclusion criteria

Exclusion criteria: 1. Received systematic treatment within 1 year (chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc); 2. Suffering from other malignant tumors; 3. Suffering from severe complications; 4. Pregnant women or lactating women.

Design outcomes

Primary

Measure	Time frame
DNA methylation level;CA19-9;	—

Countries

China

Contacts

Public ContactZhao Xudong

Peking University First Hospital

zhaoxudong512@163.com+86 010-83572437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026